Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA)

Bone Marrow Transplantation

Volumn 36, Issue 10, 2005, Pages 873-877

  Ito, J I ^a   Chandrasekar, P H ^b   Hooshmand Rad, R ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ProSanos Corporation   (United States)

Author keywords

Allogeneic; Amphotericin B lipid complex (ABLC); Aspergillosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATININE; ITRACONAZOLE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA ANALYSIS; DATA BASE; DIALYSIS; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; KIDNEY FUNCTION; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECIPIENT;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ASPERGILLOSIS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG COMBINATIONS; DRUG EVALUATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 27844472223     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705143     Document Type: Article

References (22)

1. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-1324.
2. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
4. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
5. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
6. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-1407.
7. Harbarth S, Pestotnik SL, Lloyd JF et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528-534.
8. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693.
9. Gubbins PO, Penzak SR, Polston S et al. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002; 22: 961-971.
10. Zager RA, O'Quigley J, Zager BK et al. Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 1989; 13: 210-216.
11. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
12. Pappas PG. Amphotericin B lipid complex in the treatment of invasive fungal infections: Results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis 2005; 40 (Suppl. 6): S379-S383.
13. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40 (Suppl 6): S414-S421.
14. Hooshmand-Rad R, Reed MD, Chu A et al. Retrospective study of the renal effects of Amphotericin B Lipid Complex when used at higher than recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections. Clin Ther 2004; 26: 1652-1662.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366.
17. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
18. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19: 343-347.
19. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
20. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-618.
21. Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31: 780-785.
22. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: The prospects of combination therapy. Br J Haematol 2004; 126: 165-175.